---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-006697"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:32:27.095331+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aquestive Q4 revenues down 4% YoY to $10.7M; guides FY2023 rev $37-41M; AQST-109 pivotal study on track for Q3

## Summary
- Q4 2022 total revenues $10.7M vs $11.1M YoY; net loss $12.4M ($0.23/sh) vs $28.9M ($0.72/sh) in Q4 2021.
- Full year 2022 total revenues $47.7M, down 6% YoY; net loss $54.4M ($1.12/sh) vs $70.5M ($1.85/sh).
- FY2023 guidance: total revenue $37-41M; non-GAAP adjusted EBITDA loss $31-36M.
- AQST-109 pivotal study protocol to be submitted to FDA in Q2 2023; study start expected Q3 2023.
- Patent litigation settled with BDSI for $8.5M payment to Aquestive; Indivior agreement extended to 2026 with $11.5M one-time payment.

## SEC filing metadata
- accession: 0001628280-23-006697
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828023006697/0001628280-23-006697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828023006697/aqst-20230307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-006697
- JSON: https://secwatch.observer/filing/0001628280-23-006697.json
- Plain text: https://secwatch.observer/filing/0001628280-23-006697.txt

## Key facts
- Earnings Releases
  Aquestive Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the quarter and fiscal year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000162828023006697/0001628280-23-006697-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.